Search research articles
Contact Us
Filters
Showing results (1001-1010 of 1,482) with videos related to
Page
of 149
Sort By:
Haematologica
|
April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.
Blood Cancer Journal
|
March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
The Lancet. Haematology
|
March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.
American Journal of Hematology
|
August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia
Tapan M Kadia, Farhad Ravandi, Matteo Molica, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Journal of Hematology & Oncology
|
January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
Nicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Cancer
|
October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Mahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Blood Advances
|
April 25, 2020
Clinical value of event-free survival in acute myeloid leukemia
Abhishek Maiti, Hagop M Kantarjian, Vinita Popat, et al.
American Journal of Hematology
|
April 10, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease
Andrés E Quesada, Mark J Routbort, Courtney D DiNardo, et al.
Page
of 149
Search research articles
Search
Showing results (1001-1010 of 1,482) with videos related to
Sort By:
Page
of 149
Haematologica
|
April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.
Blood Cancer Journal
|
March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
The Lancet. Haematology
|
March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.
American Journal of Hematology
|
August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia
Tapan M Kadia, Farhad Ravandi, Matteo Molica, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Journal of Hematology & Oncology
|
January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
Nicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Cancer
|
October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Mahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Blood Advances
|
April 25, 2020
Clinical value of event-free survival in acute myeloid leukemia
Abhishek Maiti, Hagop M Kantarjian, Vinita Popat, et al.
American Journal of Hematology
|
April 10, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease
Andrés E Quesada, Mark J Routbort, Courtney D DiNardo, et al.
Page
of 149